Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346853 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy
A Phase 1 study of Macular Dystrophy, Corneal, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00346853: Completed Phase 1 study of Macular Dystrophy, Corneal, sponsored by University of Utah.
NCT00346853 is a Phase 1 study of Macular Dystrophy, Corneal that has completed, run by University of Utah. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00346853, a Phase 1 study of Macular Dystrophy, Corneal, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether taking 4-methylpyrazole (4-MP, fomepizole, Antizol™) inhibits dark adaptation of the eye. In other words, we are testing if 4-MP slows the processing of vitamin A derivatives in the eye. By slowing down these processes, individuals with Stargardt disease may have better chances of saving their remaining vision. 4-MP has been shown to slow dark adaptation in animals, and is FDA approved for human use to treat individuals with methanol or ethylene glycol (antifreeze) poisoning by shutting down the body's ability to process alcohols. This medication has an excellent safety profile and has been reported to have no short-term or long-term side effects, as long as patients refrain from any alcohol while the medication is in the body. A single dose of 4-MP remains in the body for about 12 hours, and therefore, it may inhibit dark adaptation of your eyes for up to 12 hours. Studying the effects of 4-MP may lead to effective medical treatment to save Stargardt patients' vision, and may also have similar effects in other macular degenerative diseases.
Conditions Studied
Interventions
- OTHER saline
- DRUG 4-Methylpyrazole
Study Locations (1)
Utah
- Moran Eye Center, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
What the finished NCT00346853 record still lists
NCT00346853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Macular Dystrophy, Corneal appearing as the primary indexed condition, and to 2 interventions - of which saline is the first listed.
NCT00346853 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT00346853 about?
NCT00346853 is a clinical study titled "Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy". The purpose of this study is to investigate whether taking 4-methylpyrazole (4-MP, fomepizole, Antizol™) inhibits dark adaptation of the eye. In other words, we are testing if 4-MP slows the processing of vitamin A derivatives in the eye. By slowing down these processes, individuals with Stargardt d...
What is the current status of trial NCT00346853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2005-11. Estimated completion is 2006-09.
What conditions does trial NCT00346853 study?
This clinical trial studies the following conditions: Macular Dystrophy, Corneal.
What interventions are being tested in trial NCT00346853?
The interventions under investigation include: saline (OTHER), 4-Methylpyrazole (DRUG).
Who is sponsoring clinical trial NCT00346853?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00346853 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00346853's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia